Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Calliditas Therapeutics, Audiocast with teleconference, Q2'24

By Inderes8/13/2024, 12:30 PM
Calliditas Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Rene Aguilar
00:00 - 05:32

Thank you very much. Welcome to our Q2 2024 report. My name is Rene Aguilar, CEO of Calliditas. And I'm joined today by Richard Philipson, Chief Medical Officer. Fredrik Johansson, our Chief Financial Officer. And Maria Törnsén, President of North America. Next page, please. I'd like to draw your attention to the disclaimer notice, which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. And I refer to our public filings, including those containing risk factors. Next page please. So I'd like to review some of the key events in Q2, which included the conclusion of our Phase 3 study. And I figure with the readout of the open-label extension from which we reported nine-month efficacy and safety data similar to that observed in the active arm of the Phase 3 trial for those patients who were retreated with Nefecon after 15 months of observation. In April, we reported our positive topline data from our Phase 2 proof of concept study. In head and neck cancer with a lead product candidate from our novel and unique NOx inhibitor platform. Such activity showed statistically significant impact on both progression-free survival as well as overall survival. And we also were granted a new patent by the US PTO for the treatment of certain cancers, with expiration in 2039. In May, our partner Everest Medicines launched in China, and the EMA issued a positive opinion for full approval of Kinpeygo in Europe. We also participated in several important conferences where we presented additional data, which Richard will cover a bit later in the call. Next page, please. In the quarter, an offer was announced by Asahi Kasei, so on May 28th, our co-sign as a public cash offer for all shares in Calliditas for 208 Swedish crowns per share, valuing the company at approximately 1.2 billion Swedish crowns. The tender is presently ongoing, with the last day announced to be August 30th, subject to any potential extensions. The offer is recommended by the board, and around 45% of shareholders have entered into undertakings to accept the offer, subject to customary conditions. Next page. So, with regards to commercial highlights of Q2. From a commercial perspective, this quarter was a record quarter in terms of revenues, with $46.3 million of net producer revenues, representing 90% growth over the same quarter last year. In addition, we saw record enrollments with 750 new enrollments and continued strong growth in new prescribers. The strong demand we're seeing is very encouraging, and we continue to see demand in the market for TARPEYO, with summer seasonality seemingly being less pronounced this year in comparison to last year, the team during this quarter undertook a very substantial number of PMT committee meetings, and the vast majority of major plans have now updated their rules to align with the new label. We are expecting the full approval and this kind of reduced market access friction to continue to drive TARPEYO revenue growth for the year. Revenues from partners in the quarter amounted to 49 million Swedish crowns, representing growth of close to 300% compared to last quarter as Everest was launched in China also in May, operating profitability for the underlying business, excluding those costs related to the offer by Asahi Kasei for the quarter, came in at 70 million Swedish crowns, enabling us to reach our target of achieving operating profitability in the quarter. These excludes costs related to advisory services and provisions for incentive plans in connection with Asahi Kasei's offer, amounting to approximately 102 million Swedish crowns, taking us to an overall operating loss for the quarter of 31.5 million Swedish crowns. Achieving operating level profitability is a goal we were hoping to achieve and targeting in Q3, and we're obviously delighted that we reached this target already in Q2. With regards to cash, we were almost cash neutral for the quarter. For the quarter, with cash burn amounting to approximately $700,000 or 7 million crowns. We believe there will be continued profitability at the operating level for the remainder of the year, excluding any deal-related costs, based on continued revenue growth from TARPEYO and the Everest franchise as a whole. Following the quarters in July, we reported our positive data from our Phase 2 trial in PBC (Primary Biliary Cholangitis), with both the 1200 milligram doses achieving statistical significance in terms of the primary endpoint. This was a heavily pretreated population, making this outcome even more rewarding. Richard will cover these details in more depth. Richard will cover this in more detail shortly. Also in July, Calliditas was granted full approval for the treatment of Primary Biliary Cholangitis in adults by the European Commission, which also triggered a €10 million milestone payment to be recognized in Q3. With that, I'd like to hand over to Richard, who will take us through the PBC data we discussed.

Unknown 1
05:33 - 05:34

Thanks very much.

Richard Philipson
05:35 - 08:54

Renee, next slide please. On the next slide, I'd like to start by giving you a summary of the recently announced results of the Transform study of setanaxib in Primary Biliary Cholangitis, or PBC. As a reminder, this was a Phase 2b study evaluating patients aged 18 years and older with a confirmed diagnosis of Primary Biliary Cholangitis (PBC), a serum alkaline phosphatase level of 1.67 times the upper limit of normal or higher, and liver stiffness of eight kilopascals or higher as measured by FibroScan. In this double-blind, placebo-controlled study, patients were randomized to one of two doses of Calliditas sub or placebo. Patients randomized to setanaxib received either a 1200mg daily dose, administered as 800mg in the morning and 400mg in the evening, or a 1600mg daily dose administered as 800mg twice daily. Treatment was administered for 24 weeks, and the primary endpoint was the change in alkaline phosphatase at week 24 compared to baseline. Next slide. So we screened 178 patients, of whom 77 were randomized. The demographics and baseline characteristics of the trial population were representative of the target patient population, and the treatment arms were generally well-balanced. It is worth noting, as Rena has already said, that this was a heavily pretreated population. At baseline, 43.4% of patients were receiving dual therapy, that is, UDCA plus Ocaliva or UDCA plus a bile acid, and 13.2% of patients were receiving triple therapy of UDCA plus Ocaliva plus a fibrate. Next slide. With respect to the primary endpoint of change from baseline in the ratio of alkaline phosphatase at week 24, there was a statistically significant difference for both dose comparisons versus placebo. For the 1600 milligram dose group, there was a 19% difference compared to placebo, and for the 1200 milligram dose group, there was a 14% difference compared to placebo. Again, it's worth noting that although week 24 was the time point for the primary comparison, significant changes were observed from week eight onwards. Next slide. We also observed favorable improvements in liver stiffness at week 24 in patients treated with setanaxib compared to placebo. This is encouraging, as clinically relevant changes in liver stiffness are typically detectable by FibroScan over a minimum of a 52-week observation period. Next slide. Overall, 76% of Cessnock patients and 85% of placebo patients experienced at least one treatment-emergent adverse event. However, most of these were considered unrelated to the treatment.

Unknown 1
08:55 - 08:56

Serious.

Richard Philipson
08:56 - 12:28

Treatment-emergent adverse events occurred at approximately similar rates in the session. Accidentally, placebo-treated patient groups comprised 12% of Cessnock CID patients and 11.5% of placebo patients experiencing serious adverse treatment effects. Emergent adverse events and events leading to study treatment discontinuation occurred in 14% of patients and 7.7% of patients. When we look at the adverse events occurring at a frequency of 10% or higher in the overall study population, it's noteworthy that nausea, headache, and pruritus actually occurred at a higher frequency in placebo-treated patients. Arthralgia and fatigue occurred at similar frequencies in the combined setting. Active treatment groups and placebo-treated patients showed a higher frequency of nasal pharyngitis in the combined settings of the treatment group compared to placebo. So in conclusion, the primary endpoint for the study was met. Statistically significant reductions in alkaline phosphatase were observed in both sets of arms versus placebo from week eight onwards, and actually from week four onwards. When we looked at the two active doses combined, we saw favorable improvements in liver stiffness at 24 weeks in patients treated with setanaxib compared to placebo, and setanaxib was generally well tolerated. So now I'd like to move on and provide a brief update on the company's activities at ERA-EDTA this year. So, next slide. And we also presented a poster describing the outcomes of a matching-adjusted indirect comparison of EGFR in patients with IgA Nephropathy treated with Nefecon. And we also sponsored a symposium entitled 'Clinical Markers in IgA Nephropathy: Is All Proteinuria the Same?' And this was chaired by Professor Jonathan Barratt. In the latest poster presentation, we used patient-level data from our Phase 3 trial and trial-level data from the Sparse Center and Protect trial in IgA Nephropathy to estimate the relative effect of nephron with optimized RAAS inhibition compared with sparse enten on the absolute eGFR change from baseline at nine, 12, and 24 months, with common comparators of optimized renervation for guard and irbesartan for the Protect study. The results from the anchored comparison showed statistically significant favorable effects of Nipigon with optimized resin inhibition versus placebo on EGFR for all time points analyzed, as shown in the figure in the slide on the right. These results suggest that Neocon with optimized RAAS inhibition may preserve kidney function to a greater extent than the standard protocol, and provide support for Neocon as a disease-modifying therapy in IgA Nephropathy. So I'd now like to hand over to my colleague Maria Törnsén.

Rene Aguilar
12:30 - 12:33

Thank you very much, Richard. Next slide.

Unknown 1
12:33 - 12:34

Please provide the transcript that needs editing.

Rene Aguilar
12:36 - 12:37

As you recall, in.

Maria Törnsén
12:37 - 16:57

Q1 2024 was our strongest quarter since launch with 705 enrollment forms received in the second quarter of 2024. We continue to see very strong demand for TARPEYO, with 750 enrollment forms received by our patient services hub through touchpoints. Another record quarter. During the second quarter, we also gained 343 new prescribers, and we now have over 2300 healthcare providers who have prescribed RPO. We believe the strong demand we are experiencing is a result of our full approval. Our new label, with the removal of the UPC criteria and physicians recognizing TARPEYO as a disease-modifying agent that treats the disease at the source, reducing the pathogenic IgA. As mentioned, our total sales RPO in Q2 was $46 million. Another record quarter year to date with net sales for Taupo reaching $73 million, and as a result of the strong performance, we are raising our full-year guidance to $165 to $185 million for the franchise. In the second quarter, we launched our new promotional campaign highlighting the full approval and shining a light on TARPEYO for data. As you know, TARPEYO is the first and only FDA-approved product to reduce the loss of kidney function. As mentioned last quarter, we've been spending time educating US payers on the new label, and I'm pleased to report that we now have seen significant changes in key commercial plans. Over 80% of US lives are covered by commercial plans. We have aligned our policies with our new label and removed UPC completely, or reduced it to 0.8. Next slide. We are very excited about the opportunity ahead of us. We've already seen the positive reaction to the full approval of TARPEYO. We will continue to educate US healthcare professionals on this position as a disease-modifying cornerstone treatment of IgA Nephropathy. In October, we will participate in the ASEAN Congress, and we also look forward to the rollout of the guidelines in the fall. We expect the guidelines to include a repeal and also to broaden the definition of the at-risk population. As I mentioned earlier, we've seen a significant impact on payer policies in Q2, and we will continue to educate US payers to ensure more plans reflect the new TARPEYO label and secure broad access for patients. Next slide, please. TARPEYO does that by targeting the production of pathogenic IgA, as shown in the diagram. There are no other approved treatments that work in the same way. The majority of healthcare providers view TARPEYO as a disease-modifying agent that treats the disease at the source, reducing the pathogenic IgA. In market research, healthcare providers further state that the primary reasons they choose Tapia are for its efficacy in reducing UPC, significant EGFR data, favorable tolerability profile, and because Tapia is treating the underlying cause of IgA Nephropathy. With that, I will hand it over to our CFO, Fredrik Johansson, to discuss our financial results. Fredrik.

Fredrik Johansson
16:58 - 20:15

Thank you, Maria. I will now present to you the financial overview for the second quarter. As always, all numbers presented to you. Or a million unless otherwise stated. To start with, we reported $559.8 million in net revenues for the quarter. For the same quarter last year, we reported net revenues of $269.4 million. The net product sales for the quarter amounted to $493.4 million, which is a reported increase of 90% from the same quarter previous year. The remaining $66.4 million in revenue for the quarter is related to our partnerships, primarily from royalties from accrued interest and shipment of products to Everest Medicines. For the same quarter last year, we had partnership revenues of 10.1 million. Our total operating expenses for the quarter amounted to $537.8 million, compared to $330.3 million for the same quarter last year. Included in their operating expenses for the quarter. Our expenses related to the SIF offer and expenses related to provisions for Social Security contributions for incentive programs are due to the increase in our share price. That totals 101.7 million. These costs are distributed over R&D, sales and marketing, and G&A. The cost for research and development increased by 31.7 million in the quarter to 120.7 million, compared to 89 million for the same quarter the previous year. Besides the previously mentioned provisions for incentive programs, the change in the period primarily relates to increased costs for manufacturing scale-up. The cost for sales and marketing increased by 6% to $253 million in the quarter, compared to $191.5 million for the same quarter the previous year. The increase is primarily related to the scale-up of sales and marketing for the IPO in the US, following full approval and also the mentioned provisions for incentive programs. Calls for DNA increased by 8 to 9.6 million in the quarter to 166.8 million, compared to 77.2 million for the same quarter the previous year. The increased cost for DNA primarily relates to the mentioned provisions for incentive programs and advisory fees related to the public offering from Asahi Kasei. We made an operating loss in the quarter of 31.5 million, compared to an operating loss of 75.2 million for the same quarter last year. As mentioned by Rene, excluding the expenses relating to the cash offer and expenses related to provisions for Social Security contributions for the incentive programs due to an increase in the share price, we report an adjusted operating profit of 70.2 million in the second quarter. The cash flow used in operating activities in the quarter was 7 million, compared to 163 million for the same quarter the previous year. And this leaves us with a net decrease in cash in the second quarter of 11.2 million. And we continue to have a healthy cash position of 797.3 million at the end of the quarter. That was all for me. Thank you. And back to you, Renee.

Rene Aguilar
20:16 - 21:46

Thank you very much. Next slide please. Thank you. So, obviously, as we reported, Q2 was financially strong with positive progress in our pipeline. So some of the key takeaways are that we had a record quarter in terms of net product revenues from TARPEYO posting $46.3 million for the quarter, as well as the African franchise achieving approximately $53 million for the quarter. We also achieved our target of operational profitability, excluding the advisory cost and incentive program provisions as stated. We also will, with our partner, start. I was granted full approval of Kinpeygo in Europe by the European Commission. And also saw a new patent issued by the USPTO setting setanaxib active in terms of treatment of cancer with expiry of 2039. As Fredrik has said, we have a strong cash position and obviously saw an almost neutral impact on cash for the quarter. And we are expecting continued strong demand for TARPEYO for all the reasons that Maria described. And as mentioned, in terms of our revenue guidance for 2024, we're updating that to reflect these growth expectations. And so the revenue guidance for 2024 is, is updated to be 165 to 185 million USD. And with that, this concludes our Q2 2024 presentation. Thank you very much to all for listening in.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…